Compares elranatamab with standard combination treatments in relapsed multiple myeloma
Tests elranatamab against combination medicines in adults with myeloma that has returned.
Plain-language title generated from the registry record
Registry title: MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Key facts
- Where
- Belton, Beverly Hills, Boston, Chicago, Cincinnati, Cleveland, Clovis, Coral Gables, Dallas, Deerfield Beach, Doral, Encino, Evanston, Fargo, Fort Collins, Fresno, Glenview, Goodyear, Greeley, Greenville, Hawthorne, Highland Park, Hollywood, Houston, Independence, Indianapolis, Irvine, Kansas City, Lake Success, Leawood, Lincoln, Longmont, Los Angeles, Loveland, Lubbock, Madison, Manhasset, Merriam, Miami, Mobile, Morgantown, Morristown, Nashville, New Hyde Park, Newport Beach, Panorama City, Pittsburgh, Plantation, Providence, Sacramento, Springfield, Sugar Land, Tamarac, Temple, The Woodlands, Valhalla, and Zion, United StatesSee the 93 sites
- Phase
- Phase 3
Where in United States
- American Oncology Partners, P.A. Dba MidAmerica Cancer CareBelton, United StatesTaking people
- Beverly Hills Cancer CenterBeverly Hills, United StatesTaking people
- Beth Israel Deaconess Medical CenterBoston, United StatesTaking people
- BIDMC Research PharmacyBoston, United StatesTaking people
- Endeavor Health - Swedish HospitalChicago, United StatesTaking people
- Oncology Hematology Care Clinical Trials LLCCincinnati, United StatesTaking people
- The Jewish HospitalCincinnati, United StatesTaking people
- TriHealth Cancer Institute- Thomas Comprehensive Care CenterCincinnati, United StatesTaking people
- TriHealth Cancer Institute; Good Samaritan HospitalCincinnati, United StatesTaking people
- Cleveland ClinicCleveland, United StatesTaking people
- Clovis Community Medical CenterClovis, United StatesTaking people
- Community Cancer InstituteClovis, United StatesTaking people
- Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical CenterCoral Gables, United StatesTaking people
- Baylor University Medical CenterDallas, United StatesTaking people
- Baylor University Medical Center, Investigational Drug Services, Department of PharmacyDallas, United StatesTaking people
- University of Miami Hospital and Clinics Deerfield BeachDeerfield Beach, United StatesTaking people
- Sylvester Comprehensive Cancer Center- DoralDoral, United StatesTaking people
- Clinical Research Advisors (Encino Satellite Location)Encino, United StatesTaking people
- Endeavor Health - Evanston HospitalEvanston, United StatesTaking people
- Sanford Fargo Medical CenterFargo, United StatesTaking people
- UCHealth HarmonyFort Collins, United StatesTaking people
- UCHealth Poudre Valley HospitalFort Collins, United StatesTaking people
- Community Regional Medical CenterFresno, United StatesTaking people
- University of California San FranciscoFresno, United StatesTaking people
- Endeavor Health - Glenbrook Hospital Ambulatory Care CenterGlenview, United StatesTaking people
- Western Regional Medical Center, Inc. dba. City of Hope PhoenixGoodyear, United StatesNo longer taking part
- UCHealth Greeley HospitalGreeley, United StatesTaking people
- St Francis Cancer CenterGreenville, United StatesNo longer taking part
- WMCHealth Advanced Physician ServicesHawthorne, United StatesNo longer taking part
- Endeavor Health - Highland Park Hospital Health Center 1Highland Park, United StatesTaking people
- Sylvester Comprehensive Cancer Center - HollywoodHollywood, United StatesTaking people
- Houston Methodist Cancer Center InfusionHouston, United StatesTaking people
- Houston Methodist Clear Lake Hospital (St. John)Houston, United StatesTaking people
- Houston Methodist Hospital - Department of PharmacyHouston, United StatesTaking people
- Houston Methodist Hospital Cancer CenterHouston, United StatesTaking people
- Houston Methodist West HospitalHouston, United StatesTaking people
- Houston Methodist Willowbrook HospitalHouston, United StatesTaking people
- MIVA MedicalIndependence, United StatesTaking people
- Community Health Network, IncIndianapolis, United StatesTaking people
- Hoag Health Center IrvineIrvine, United StatesNo longer taking part
- Hoag Hospital IrvineIrvine, United StatesNo longer taking part
- American Oncology Partners, P.A. Dba MidAmerica Cancer CareKansas City, United StatesTaking people
- Kansas City VA Medical CenterKansas City, United StatesTaking people
- Northwell Health/ RJ Zuckerberg Cancer CenterLake Success, United StatesTaking people
- Ascentist Doctors' HospitalLeawood, United StatesTaking people
- Bryan Medical CenterLincoln, United StatesTaking people
- NHO Revive Research Institute, LLCLincoln, United StatesTaking people
- UCHealth Longs Peak HospitalLongmont, United StatesTaking people
- UCHealth Longs Peak Medical CenterLongmont, United StatesTaking people
- Clinical Research Advisors (Korea Town Satellite Location)Los Angeles, United StatesTaking people
- Clinical Research Advisors (West Hollywood Satellite Location)Los Angeles, United StatesTaking people
- Valkyrie Clinical TrialsLos Angeles, United StatesTaking people
- UCHealth - Medical Center of the RockiesLoveland, United StatesTaking people
- Joe Arrington Cancer Research and Treatment CenterLubbock, United StatesTaking people
- University of Wisconsin Carbone Cancer Center - Eastpark Medical CenterMadison, United StatesTaking people
- University of Wisconsin Carbone Cancer Center - University HospitalMadison, United StatesTaking people
- North Shore University HospitalManhasset, United StatesTaking people
- American Oncology Partners, P.A. Dba MidAmerica Cancer CareMerriam, United StatesTaking people
- Baptist Hospital of MiamiMiami, United StatesTaking people
- Miami Cancer Institute at Baptist Health, Inc.Miami, United StatesTaking people
- Sylvester Comprehensive Cancer Center - KendallMiami, United StatesTaking people
- Sylvester Comprehensive Cancer Center*Miami, United StatesTaking people
- University of Miami Hospital and ClinicsMiami, United StatesTaking people
- University of Miami Hospital and Clinics - Griffin Cancer Research BuildingMiami, United StatesTaking people
- Infirmary Cancer CareMobile, United StatesTaking people
- WVU Cancer InstituteMorgantown, United StatesTaking people
- Atlantic Health System / Morristown Medical CenterMorristown, United StatesTaking people
- Ascension St. Thomas HospitalNashville, United StatesTaking people
- Tennessee Oncology, PLLC - Investigational Drug ServicesNashville, United StatesTaking people
- Tennessee Oncology, PLLC - Nashville Elliston Place Plaza Center for Blood CancersNashville, United StatesTaking people
- Tennessee Oncology, PLLC - Nashville Elliston Place Plaza DDUNashville, United StatesTaking people
- Tennessee Oncology, PLLC - Nashville Elliston Place Plaza Medical Oncology & HematologyNashville, United StatesTaking people
- Long Island Jewish Medical CenterNew Hyde Park, United StatesTaking people
- Hoag Memorial Hospital PresbyterianNewport Beach, United StatesNo longer taking part
- Mission Community Hospital (Satellite Site)Panorama City, United StatesTaking people
- AHN West Penn HospitalPittsburgh, United StatesTaking people
- BRCR globalPlantation, United StatesTaking people
- BRCR Medical Center IncPlantation, United StatesTaking people
- HCA Florida Westside HospitalPlantation, United StatesTaking people
- Rodhe Island HospitalProvidence, United StatesTaking people
- The Miriam HospitalProvidence, United StatesTaking people
- University of CaliforniaSacramento, United StatesTaking people
- University of California Davis (UC Davis) Comprehensive Cancer CenterSacramento, United StatesTaking people
- HSHS St. John's HospitalSpringfield, United StatesTaking people
- Simmons Cancer Institute at SIUSpringfield, United StatesTaking people
- Springfield Clinic Main CampusSpringfield, United StatesTaking people
- Springfield Memorial HospitalSpringfield, United StatesTaking people
- Houston Methodist Sugar Land HospitalSugar Land, United StatesTaking people
- BRCR Medical Center Inc.Tamarac, United StatesTaking people
- Baylor Scott & White Medical Center - TempleTemple, United StatesTaking people
- Houston Methodist The Woodlands HospitalThe Woodlands, United StatesTaking people
- Westchester Medical CenterValhalla, United StatesNo longer taking part
- Midwestern Regional Medical Center, Inc. dba City of Hope ChicagoZion, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pfizer
- Trial code
- NCT06152575EU 2023-507871-23-00
- Record updated
- 24 August 2026
- Original description
The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer).Read full original descriptionShow less
A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE (PVd) OR CARFILZOMIB, DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTI-CD38 DIRECTED THERAPY
The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer).
This study is seeking participants who:
* Are 18 years of age or older and have MM. * Have received treatments before for MM. * Have MM that has returned or not responded to their most recent treatment.
Half of the participants will receive elranatamab. The other half of participants will receive a combination therapy selected by the study doctor. The selected combination therapy will include 2 to 3 different medicines commonly used to treat MM.
Elranatamab will be given as a shot under the skin at the study clinic about once a week. This may change to a smaller number of shots later in the study.
The medicines in the combination therapy will be taken by mouth (at home or at the study clinic) AND will be given either as:
* a shot under the skin at the study clinic * through a needle in the vein at the study clinic The number of times these medicines will be taken depends on what combination therapy the study doctor selects.
Participants may continue to receive elranatamab or a combination therapy until their MM is no longer responding. The study team will see how each participant is doing with the study treatment during regular visits at the study clinic. The study team will continue to follow-up with participants after study treatment with telephone contacts (or visits).
The study will compare the experiences of people receiving elranatamab to those people receiving a combination therapy. This will help learn about the safety and how effective elranatamab is.
Inclusion: Prior diagnosis of multiple myeloma as defined by International Myeloma Working Group (IMWG) criteria and previously received 1 to 4 prior lines of therapy including prior anti-cluster of differentiation 38 (CD38) antibody and prior lenalidomide; Documented evidence of progressive disease or failure to achieve a response to last line of therapy per IMWG criteria; Measurable disease defined as at least 1 of the following: (a) Serum M-protein ≥0.5 g/dL; (b) Urinary M-protein excretion ≥200 mg/24 hours; (c) Serum involved immunoglobulin FLC ≥10 mg/dL AND abnormal serum immunoglobulin kappa to lambda FLC ratio (<0.26 or >1.65); Have clinical laboratory values within the specified range; ECOG (Eastern Cooperative Oncology Group) performance status ≤2; Not pregnant or breastfeeding and willing to use contraception.
Exclusion: Stem cell transplant within 12 weeks prior to enrolment, or active graft versus host disease; Any other active malignancy within 3 years prior to enrolment (exceptions include, adequately treated basal cell or squamous cell skin cancer, carcinoma in situ); Previous treatment with a B cell maturation antigen (BCMA)-directed therapy or CD3-redirecting therapy; Unable to receive investigator's choice therapy; Live attenuated vaccine within 4 weeks of the first dose of study intervention; Administration with an investigational product (e.g. drug or vaccine) within 30 days preceding the first dose of study intervention used in this study; Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin abnormalities (POEMS) syndrome; Any active, uncontrolled bacterial, fungal, or viral infection; Smoldering multiple myeloma; Plasma cell leukemia; Amyloidosis; Known central nervous system (CNS) involvement or clinical signs of myelomatous meningeal involvement.